When should a myeloproliferative syndrome be suggested in vascular medicine?;quand évoquer un syndrome myéloprolifératif en pathologie vasculaire?

Journal des Maladies Vasculaires

Volumn 30, Issue 1, 2005, Pages 46-52

  Lazareth, I ^a   Delarue, R ^a,b   Priollet, P ^a  

^a SAINT JOSEPH HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ERYTHROPOIETIN; HYDROXYUREA;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BRAIN CIRCULATION; BUDD CHIARI SYNDROME; CLINICAL FEATURE; DRUG SENSITIVITY; HISTOPATHOLOGY; HUMAN; LEG ULCER; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; REVIEW; SPLANCHNIC BLOOD FLOW; THROMBOCYTHEMIA; VASCULAR DISEASE; VEIN THROMBOSIS;

EID: 17444424317     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0398-0499(05)83794-1     Document Type: Review

References (30)

1. MURPHY S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Sem Hematol, 1999; 36: 9-13.
2. SPIVAK JL, BAROSI G, TOGNONI G et al. Chronic myeloproliferative disorders. Hematology, 2003; 200-24.
3. LANDOLFI R, MARCHIOLI R, KUTTI J et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med, 2004; 350: 114-24.
4. RINDER HM, SCHUSTER JE, RINDER CS, WANG C, SCHWEIDLER HJ, SMITH BR. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood, 1998; 91: 1288-94.
5. RUGGERI M, TOSETTO A, FREZZATO M, RODEGHIERO F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med, 2003; 139: 470-5.
6. BARABAS AP, OFFEN DN, MEINHARD EA. The arterial complications of polycythaemia vera. Br J Surg, 1973; 60: 183-7.
7. EDWARDS EA, COOLEY MH. Peripheral vascular symptoms as the initial manifestation of polycythemia vera. JAMA, 1970; 23: 1463-7.
8. BAZZAN M, TAMPONI G, SCHINCO P et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol, 1999; 78: 539-43.
9. MENON KVN, SHAH V, KAMATH PS. The Budd-Chiari syndrome. N Engl J Med, 2004; 350: 578-85.
10. DE STEFANO V, TEOFILI L, LEONE G, MICHIELS JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost, 1997; 23: 411-8.
11. VALLA D, CASADEVALL N, LACOMBE C and al. Primary myeloproliferative disorder and hepatic vein thrombosis. Ann Intern Med, 1985; 103: 329-34.
12. TEOFILI L, DE STEFANO V, LEONE G et al. Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thromb Haemost, 1992; 67: 297-301.13.
13. GANTI AK, POTTI A, KOKA VK, PERVEZ H, MEHDI SA. Myeloproliferative syndromes and the associated risk of coronary artery disease. Thromb Res, 2003; 110: 83-6.
14. VAN GENDEREN PJ, MULDER PG, WALEBOER M, VAN DE MOESDIJK, MICHIELS JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol, 1997; 97: 179-84.
15. MICHIELS JJ, VAN GENDEREN PJ, LINDEMANS J, VAN VLIET HH. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leak Lymph, 1996; 22 (supl): 47-56.
16. KOUDSTAAL PJ, KOUDSTAAL A. Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. Semin Thromb Haemost 1997; 23: 365-70.
17. BADER U, BANYAI M, BONI R, BURG G, HAFNER J. Leg ulcers in patients with myeloproliferative disorders: disease-or treatment-related? Dermatology, 2000; 200: 45-8.
18. SIRIEIX ME, DEBURE C, BAUDOT N et al. Leg ulcers and hydroxyurea. Arch Dermatol, 1999; 135: 818-20.
19. MICHIELS JJ, JUVONEN E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the polycythemia vera study group. Semin Thromb Haemost, 1997; 23: 339-47.
20. PEARSON TC, MESSINEZY M, WESTWOOD N et al. A polycythemia vera update: diagnosis, pathobiology and treatment. Hematology, 2000: 51-68.
21. TEFFERI A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc, 2003; 78: 174-94.
22. SACCHI S, VINCI G, GUGLIOTTA L et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600×1000000000/L. Haematologica, 2000; 85: 492-5.
23. PEARSON TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol, 2002; 29 (sup10): 16-21.
24. CORTELAZZO S, FINAZZI G, RUGGERI M et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med, 1995; 332: 1132-6.
25. PASSAMONTI F, MALABARBA L, ORLANDI E et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica, 2003; 88: 13-8.
26. RANDI ML, ROSSI C, FABRIS F, GIROLAMI A. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy-a follow-up study in 68 patients. Clin Appl Thrombosis/Hemostasis, 2000; 6: 31-5.
27. RUGGERI M, GISSLINGER H, TOSETTO A and al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol, 2002; 71: 1-6.
28. HARRISON CN, DONOHOE S, CARR P, DAVE M, MACKIE I, MACHIN SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost, 2002; 87: 802-7.
29. AMITRANO L, GUARDASCIONE MA, AMES PRJ et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol, 2003; 72: 75-81.
30. GISSLINGER H, RODEGHIERO F, RUGGERI M et al. Homocysteine levels in polycythemia vera and essential thrombocythaemia. Br J Haematol, 1999; 105: 551-5.